Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IbrutiNib in SARS CoV-2 Induced Pulmonary Injury and Respiratory Failure (iNSPIRE)

Next Previous
X
Search
Trial Profile

IbrutiNib in SARS CoV-2 Induced Pulmonary Injury and Respiratory Failure (iNSPIRE)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibrutinib (Primary)
  • Indications COVID 2019 infections; Lung injury; Respiratory insufficiency
  • Focus Therapeutic Use
  • Acronyms iNSPIRE
  • Sponsors AbbVie

    • Most Recent Events

    • 07 Jul 2021 Status changed from active, no longer recruiting to completed.
    • 13 Apr 2021 Planned End Date changed from 25 Aug 2021 to 11 Jun 2021.
    • 13 Apr 2021 Planned primary completion date changed from 19 Mar 2021 to 10 May 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top